natgillin/translations-raw huggingface dataset:
Alopeci, dermatitis, tør hud, erythema, flushing, fotosensitivitet, pruritus, udslæt, urticaria, svedtendens.
Alopecia, dermatitis, dry skin, erythema, flushing, photosensitivity, pruritus, rash, urticaria, sweating
Ikke almindelig:
Muscle cramp, back pain, leg pain, myalgia Uncommon:
Smerter i armene, ledhævelse, smerter i knæene, knogle -, led - og muskelsmerter, skuldersmerter, stivhed, arthralgi, arthritis, koksalgi, fibromyalgi, muskelsvaghed.
Arm pain, joint swelling, knee pain, musculoskeletal pain, shoulder pain, stiffness, arthralgia, arthritis, coxalgia, fibromyalgia, muscle weakness
Nykturi, hyppig vandladning, urinvejsinfektion.
Nocturia, urinary frequency, urinary tract infection
Nedsat libido, impotens.
Decreased libido, impotence
27 Almene symptomer og reaktioner på administrationsstedet Almindelig:
General disorders and administration site conditions Common:
Asteni, fatigue, smerter i brystet.
Asthenia, fatigue, chest pain
Ikke almindellig:
28 Uncommon:
Faciale ødemer, feber.
Facial oedema, fever
Ikke almindelig:
Hyperkalaemia, mild reduction of haematocrit and haemoglobin Uncommon:
Lille stigning i urinstof og serumkreatininkoncentration.
Mild increase in urea and creatinine serum levels Very rare:
Stigning i leverenzymer og bilirubin.
Increase in hepatic enzymes and bilirubin.
Blod og lymfesystemet Ikke almindelig:
Blood and lymphatic system disorders Uncommon:
Agranulocytose, aplastisk anæmi, hæmolytisk anæmi, leukopeni, purpura, trombocytopeni.
Agranulocytosis, aplastic anaemia, haemolytic anaemia, leukopenia, purpura, thrombocytopenia
Anafylaktisk reaktion.
Anaphylactic reaction
Anoreksi, hyperglykæmi, hyperurikæmi, hypokaliæmi, hyponatriæmi.
Anorexia, hyperglycaemia, hyperuricaemia, hypokalaemia, hyponatraemia
Søvnløshed.
Insomnia
Cefalalgi.
Cephalalgia
Vaskulære sygdomme Ikke almindelig:
Transient blurred vision, xanthopsia Vascular disorders Uncommon:
Nekrotiserende angitis (vasculitis, kutan vasculitis).
Necrotizing angiitis (vasculitis, cutaneous vasculitis)
Respirationsbesvær, herunder pneumonitis og lungeødem.
Respiratory distress including pneumonitis and pulmonary oedema
Mave- tarmkanalen Ikke almindelig:
Gastrointestinal disorders Uncommon:
Sialoadenitis, spasmer, maveirritation, kvalme, opkastning, diarré, forstoppelse.
Sialoadenitis, spasms, stomach irritation, nausea, vomiting, diarrhoea, constipation
Lever og galdeveje Ikke almindelig:
Hepato-biliary disorders Uncommon:
Icterus (intrahepatisk galdestase), pankreatitis.
Icterus (intrahepatic cholestatis), pancreatitis
Fotosensitivitet, urticaria, toksisk epidermal nekrolyse.
Photosensitivity, urticaria, toxic epidermal necrolysis
Knogler, led, muskler og bindevæv Ikke almindelig:
Musculoskeletal and connective tissue disorders Uncommon:
Muskelkramper.
Muscle cramps
Glukosuri, interstitiel nefritis, renal dysfunktion, nyresvigt.
Glycosuria, interstitial nephritis, renal dysfunction, renal failure
Feber, svimmelhed.
Fever, dizziness
Hvis indtagelsen er sket for kort tid siden, foreslås det at fremkalde opkastning.
Suggested measures include induction of emesis if ingestion is recent, and
Korrektion af væske - og elektrolytbalance, hepatisk koma og hypotension behandles henhold til gældende procedurer.
29 correction of dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures.
Losartan Begrænsede data er tilgængelige med hensyn til overdosering hos mennesker.
Losartan Limited data are available in regard to overdosage in humans.
Hydrochlorthiazid De mest almindelige observerede tegn og symptomer er elektrolytdepletering (hypokaliæmi, hypochloræmi, hyponatriæmi) og dehydrering som resultat af kraftig diurese.
Hydrochlorothiazide The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis.
Kombination af angiotensin II- receptor( type AT1) - antagonist og thiaziddiuretikum, antihypertensivum, ATC- kode:
Combination containing an angiotensin II-receptor(type AT1)-antagonist and a thiazide diuretic, Antihypertensive, ATC code:
5. 1 Farmakodynamiske egenskaber
Losartan-Hydrochlorothiazide
Som resultat af den diuretiske virkning af hydrochlorthiazid øges plasmareninaktiviteten og aldosteronsekretionen, serumkalium falder, og koncentrationen af angiotensin- II reduceres.
Further, as a result of its diuretic effect, hydrochlorothiazide increases plasma renin activity, increases aldosterone secretion, decreases serum potassium, and increases the levels of angiotensin II.
Administration af losartan blokerer alle fysiologisk relevante virkninger af angiotensin- II, og ved hæmning af aldosteron kan dette måske forstærke det tab af kalium, som er associeret med diuretika.
Administration of losartan blocks all the physiologically relevant actions of angiotensin II and through inhibition of aldosterone could tend to attenuate the potassium loss associated with the diuretic.
Efter 12 ugers behandling i kliniske undersøgelser med losartan 50 mg/ hydrochlor - thiazid 12, 5 mg, blev lavest målte, siddende diastole blodtryk reduceret med gennemsnitligt 13, 2 mmHg.
In clinical trials, after 12 weeks of therapy with losartan 50 mg/ hydrochlorothiazide 12.5 mg, trough sitting diastolic blood pressure was reduced by an average of up to 13.2 mmHg.
Cozaar Comp. er effektiv ved alle grader af hypertension.
Cozaar Comp is effective in reducing blood pressure in males and females, blacks and non-blacks and in younger (< 65 years) and older (≥ 65 years) patients and is effective in all degrees of hypertension.
29 Losartan
Losartan
Losartan er en syntetisk, oral angiotensin- II- receptorantagonist (type AT1).
Losartan is a synthetically produced oral angiotensin-II receptor (type AT1) antagonist.
Angiotensin- II, der er en potent vasokonstriktor, er det primære aktive hormon i renin- angiotensinsystemet og en betydningsfuld determinant for hypertensions patofysiologi.
Angiotensin II, a potent vasoconstrictor, is the primary active hormon of the renin-angiotensin system and an important determinant of the pathophysiology of hypertension.
Angiotensin- II stimulerer også formeringen af celler i den glatte muskulatur.
Angiotensin II binds to the AT1 receptor found in many tissues (e. g. vascular smooth muscle, adrenal gland, kidneys and the heart)
Losartan blokerer selektivt AT1- receptoren.
Losartan selectively blocks the AT1 receptor.
In vitro og in vivo blokerer losartan og dennes farmakologisk aktive carboxylsyremetabolit E- 3174 alle fysiologisk relevante virkninger af angiotensin- II, uafhængig af kilde eller syntesevej.
In vitro and in vivo losartan and its pharmacologically active carboxylic acid metabolite E-3174 block all physiologically relevant actions of angiotensin II, regardless of the source or route of its synthesis.
Under administration af losartan fører fjernelse af angiotensin- II’ s negative feedback på reninsekretionen til øget plasmareninaktivitet (PRA).
During the administration of losartan the removal of the angiotensin II negative feedback on renin secretion leads to increased plasma-renin activity (PRA).
Øget PRA fører til øget koncentration af angiotensin- II i plasma.
Increase in the PRA leads to an increase in angiotensin II in plasma.
Selv med disse stigninger bibeholdes den antihypertensive aktivitet og suppressionen af plasmaaldosteronkoncentrationen, hvilket tyder på angiotensin- II- receptorblokering.
Despite these increases, antihypertensive activity and suppression of the plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade.
Efter seponering af losartan faldt PRA og angiotensin- II- værdierne inden for tre dage til værdierne ved baseline.
After the discontinuation of losartan, PRA and angiotensin II values fell within 3 days to the baseline values.
Både losartan og dets primære aktive metabolit har meget større affinitet over for AT1- receptoren end over for AT2- receptoren.
Both losartan and its principal active metabolite have a far greater affinity for the AT1 receptor than for the AT2 receptor.
Den aktive metabolit er 10- 40 gange mere aktiv end losartan på vægtbasis.
The active metabolite is 10- to 40-times more active than losartan on a weight for weight basis.
I en undersøgelse som var specielt designet til at vurdere incidensen af hoste hos patienter, der blev behandlet med losartan sammenlignet med patienter, der fik ACE- hæmmere, var incidensen af hoste, der blev rapporteret af de patienter, der fik losartan eller hydrochlorthiazid den samme, og den var signifikant mindre end hos de patienter, der blev behandlet med en ACE- hæmmer.
In a study specifically designed to assess the incidence of cough in patients treated with losartan as compared to patients treated with ACE inhibitors, the incidence of cough reported by patients receiving losartan or hydrochlorothiazide was similar and was significantly less than in patients treated with an ACE inhibitor.
I en samlet analyse af 16 dobbeltblindede kliniske undersøgelser med 4131 patienter, var incidensen af spontant rapporteret hoste hos patienter, der fik losartan den samme (3, 1%) som hos de patienter, der fik placebo (2, 6%) eller hydrochlorthiazid (4, 1%), hvorimod incidensen med ACE- hæmmere var 8, 8%).
In addition, in an overall analysis of 16 double-blind clinical trials in 4131 patients, the incidence of spontaneously reported cough in patients treated with losartan was similar (3.1%) to that of patients treated with placebo (2.6%) or hydrochlorothiazide (4.1%), whereas the incidence with ACE inhibitors was 8.8%.
Hos ikke- diabetiske, hypertensive patienter med proteinuri gav administration af losartankalium signifikant reduktion i proteinuri, fraktioneret ekskretion af albumin og IgG.
In nondiabetic hypertensive patients with proteinuria, the administration of losartan potassium significantly reduces proteinuria, fractional excretion of albumin and IgG.
Generelt gav losartan et fald i serumurinsyre (sædvanligvis < 0, 4 mg/ dl), som var vedvarende ved kronisk terapi.
Generally losartan causes a decrease in serum uric acid (usually < 0.4 mg/ dL) which was persistent in chronic therapy.
Blodtryksmåling 24 timer efter dosering i forhold til 5- 6 timer efter dosering viste reduktion af blodtrykket i løbet af 24 timer; den naturlige døgnrytme blev bibeholdt.
Measurements of blood pressure 24 hours post-dose relative to 5 – 6 hours post-dose demonstrated blood pressure reduction over 24 hours; the natural diurnal rhythm was retained.
Reduktion af blodtrykket i slutningen af dosisintervallet var 70- 80% af effekten set 5- 6 timer efter dosering.
Blood pressure reduction at the end of the dosing interval was 70 – 80% of the effect seen 5-6 hours post- dose.
30 Seponering af losartan hos hypertensive patienter medførte ikke en brat stigning af blodtrykket (rebound).
Discontinuation of Losartan in hypertensive patients did not result in an abrupt rise in blood pressure (rebound).
Losartan er lige effektiv hos mænd og kvinder samt hos yngre (< 65 år) og ældre hypertensive patienter.
31 Losartan is equally effective in males and females, and in younger (below the age of 65 years) and older hypertensive patients.
LIFE- undersøgelsen LIFE (The Losartan Intervention For Endpoint Reduction In Hypertension) var en randomiseret, trippelblindet, aktiv kontrolleret undersøgelse foretaget hos 9193 hypertensive patienter i alderen 55- 80 år med EKG- diagnosticeret hypertrofi af venstre ventrikel.
LIFE Study The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was a randomised, triple-blind, active-controlled study in 9193 hypertensive patients aged 55 to 80 years with ECG- documented left ventricular hypertrophy.
Hvis det forud fastsatte blodtryk (< 140/ 90 mmHg) ikke blev nået, tilføjedes først hydrochlorthiazid (12, 5 mg) og hvis nødvendigt blev dosis af losartan eller atenolol øget til 100 mg én gang dagligt.
If goal blood pressure (< 140/ 90 mmHg) was not reached, hydrochlorothiazide (12.5 mg) was added first and, if needed, the dose of losartan or atenolol was then increased to 100 mg once daily.
Andre antihypertensiva, undtagen ACE- hæmmere, angiotensin II- antagonister eller betablokkere, blev tilføjet hvis dette var nødvendigt for at opnå det ønskede blodtryk.
Other antihypertensives, with the exception of ACE inhibitors, angiotensin II antagonists or beta-blockers were added if necessary to reach the goal blood pressure.
Den gennemsnitlige opfølgningstid var 4, 8 år.
The mean length of follow up was 4.8 years.
Behandlingen med losartan resulterede i en risikoreduktion på 13% (p=0, 021, 95% konfidensinterval 0, 77- 0, 98) sammenlignet med atenolol for patienter, der nåede det primære sammensatte effektmål.
Treatment with losartan resulted in a 13.0% risk reduction (p=0.021, 95% confidence interval 0.77-0.98) compared with atenolol for patients reaching the primary composite endpoint.
Behandling med losartan reducerede risikoen for stroke med 25% i forhold til atenolol (p=0, 001, 95% konfidensinterval 0, 63- 0, 89).
Treatment with losartan reduced the risk of stroke by 25% relative to atenolol (p=0.001 95% confidence interval 0.63-0.89).
Renin- aldosteronbindingen medieres af angiotensin II, og derfor er der tendens til at kaliumtabet, der er forbundet med thiaziddiuretika, ændres, når en angiotensin II- receptoantagonist gives samtidigt.
The renin-aldosterone link is mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics.
Den antihypertensive virkning varer ved i op til 24 timer.
After oral use, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours the antihypertensive effect persists for up to 24 hours.
Losartan Efter oral administration absorberes losartan godt og undergår firstpass metabolisme, hvorved der dannes en aktiv carboxylsyremetabolit og andre inaktive metabolitter.
Losartan Following oral administration, losartan is well absorbed and undergoes first-pass metabolism, forming an active carboxylic acid metabolite and other inactive metabolites.
33%.
The systemic bioavailability of losartan tablets is approximately 33%.
Losartans og dets aktive metabolits gennemsnitlige maksimalkoncentration nås i løbet af henholdsvis 1 time og 3- 4 timer.
Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively.
31 Distribution
Distribution
Losartan Både losartan og dets aktive metabolit bindes ≥99% til plasmaproteiner, primært albumin.
Losartan Both losartan and its active metabolite are ≥ 99% bound to plasma proteins, primarily albumin.
Undersøgelser med rotter viser, at losartan næppe passerer blod- hjernebarrieren.
Studies in rats indicate that losartan crosses the blood- brain barrier poorly, if at all.
Hydrochlorthiazid Hydrochlorthiazid passerer placentabarrieren, men ikke blod- hjernebarrieren og udskilles i modermælk.
32 Hydrochlorothiazide Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
14% af en intravenøs eller oralt administreret dosis af losartan omdannes til dets aktive metabolit.
Losartan About 14% of an intravenously- or orally-administered dose of losartan is converted to its active metabolite.
Efter oral og intravenøs administration af 14C- mærket losartankalium, er cirkulerende plasmaradioaktivitet primært knyttet til losartan og dets aktive metabolit.
Following oral and intravenous administration of 14C-labeled losartan potassium, circulating plasma radioactivity primarily is attributed to losartan and its active metabolite.
1% af de undersøgte individer.
Minimal conversion of losartan to its active metabolite was seen in about one percent of individuals studied.
Ud over den aktive metabolit dannes inaktive metabolitter, herunder 2 hovedmetabolitter dannet ved hydroxylering af butylsidekæden og en metabolit af mindre betydning, en N- 2- tetrazolglucuronid.
In addition to the active metabolite, inactive metabolites are formed, including two major metabolites formed by hydroxylation of the butyl side chain and a minor metabolite, an N-2 tetrazole glucuronide.
600 ml/ min og 50 ml / min.
Losartan Plasma clearance of losartan and its active metabolite is about 600 mL/ min and 50 mL/ min, respectively.
74 ml/ min og 26 ml/ min.
Renal clearance of losartan and its active metabolite is about 74 mL/ min and 26 mL/ min, respectively.
6% af dosis udskilles via urinen som aktiv metabolit.
When losartan is administered orally, about 4% of the dose is excreted unchanged in the urine, and about 6% of the dose is excreted in the urine as active metabolite.
2 timer og 6- 9 timer.
Following oral administration, plasma concentrations of losartan and its active metabolite decline polyexponentially with a terminal half-life of about 2 hours and 6-9 hours, respectively.
Ved dosering én gang dagligt med 100 mg akkumuleres hverken losartan eller dets aktive metabolit i plasma signifikant.
During once- daily dosing with 100 mg, neither losartan nor its active metabolite accumulates significantly in plasma.
35% af radioaktiviteten genfundet i urin og 58% i fæces.
Following an oral dose of 14C-labeled losartan in man, about 35% of radioactivity is recovered in the urine and 58% in the feces.
Hydrochlorthiazid Hydrochlorthiazid metaboliseres ikke, men udskilles hurtigt via nyrerne.
Hydrochlorothiazide Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.
Hvis plasmakoncentrationen følges i mindst 24 timer er plasmahalveringstiden set at variere mellem 5, 6 og 14, 8 timer.
When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.
Losartan- hydrochlorthiazid Losartans og dets aktive metabolits plasmakoncentration samt absoprtionen af hydrochlorthiazid hos ældre hypertensive patienter var ikke signifikant forskellig fra den, der sås hos unge hypertensive patienter.
Losartan-Hydrochlorothiazide The plasma concentrations of losartan and its active metabolite and the absorption of hydrochlorothiazide in elderly hypertensives are not significantly different from those in young hypertensives.
Losartan Hos patienter med mild til moderat alkoholinduceret levercirrose var losartans og dets aktive metabolits plasmakoncentration efter oral administration henholdsvis 5 og 1, 7 gange højere end hos unge frivillige mænd.
Losartan Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan and its active metabolite were, respectively, 5-fold and 1.7-fold greater than those seen in young male volunteers.
Hverken losartan eller dets aktive metabolit kan fjernes ved hæmodialyse.
Neither losartan nor the active metabolite can be removed by hemodialysis.
Losartan/ hydrochlorthiazids toksiske potential blev vurderet i gentagne toksicitetsundersøgelser af op til 6 måneders varighed hos rotter og hunde efter oral administration.
The toxic potential of the combination of
De observerede ændringer i disse kombinationsundersøgelser dannedes hovesageligt af losartankomponenten.
33 losartan/ hydrochlorothiazide was evaluated in chronic toxicity studies for up to six months duration in rats and dogs after oral administration, and the changes observed in these studies with the combination were mainly produced by the losartan component.
Administration af losartan/ hydrochlorthiazid - kombinationen inducerede et fald i de røde blodcelleparametre (erytrocytter, hæmoglobin, hæmatokrit), en stigning i urinstof- N i serum, fald i hjertevægt (uden histologisk korrelat) og gastrointestinale forandringer (læsion af slimhindemembranen, mavesår, erosioner, blødninger).
The administration of the losartan/ hydrochlorothiazide combination induced a decrease in the red blood cell parameters (erythrocytes, haemoglobin, haematocrit), a rise in urea-N in the serum, a decrease in heart weight (without a histological correlate) and gastrointestinal changes (mucous membrane lesions, ulcers, erosions, haemorrhages).
Der var ikke tegn på teratogenicitet hos rotter eller kaniner, der havde fået behandling med losartan/ hydrochlorthiazid- kombinationen.
There was no evidence of teratogenicity in rats or rabbits treated with the losartan/ hydrochlorothiazide combination.
Føtal toksicitet hos rotter, som fremgik af en let stigning i overtallige ribben i F1- generationen, sås når hunrotter blev behandlet før og under gestationen.
Foetal toxicity in rats, as evidenced by a slight increase in supernumerary ribs in the F1 generation, was observed when females were treated prior to and throughout gestation.
Som det sås i undersøgelser med losartan alene, forekom føtale og neonatale bivirkninger, herunder nyretoksicitet og fosterdød, når gravide rotter blev behandlet med losartan/ hydrochlorthiazidkombinationen sent i gestationen og/ eller diegivningen.
As observed in studies with losartan alone, adverse foetal and neonatal effects, including renal toxicity and foetal death, occurred when pregnant rate were treated with the losartan/ hydrochlorothiazide combination during late gestation and/ or lactation.
Hver tablet indeholder følgende inaktive indholdsstoffer:
Cozaar Comp 50 mg/ 12.5 mg, Cozaar Comp 100 mg/ 12.5 mg and Cozaar Comp 100 mg/ 25 mg:
Mikrokrystallinsk cellulose (E460) Lactosemonohydrat Prægelatineret majsstivelse Magnesiumstearat (E572) Hydroxypropylcellulose (E463) Hypromellose (E464)
Each tablet contains the following inactive ingredients: microcrystalline cellulose(E460), lactose monohydrate, pregelatinized maize starch, magnesium stearate (E572), hydroxypropyl cellulose (E463), hypromellose(E464).
Cozaar Comp.
Cozaar Comp 50 mg/ 12.5 mg contains 4.24 mg (0.108 mEq) of potassium.
100 mg/ 25 mg indeholder 8, 48 mg (0, 216 mEq) kalium.
Cozaar Comp 100 mg/ 12.5 mg mg contains 8.48 mg (0.216 mEq) of potassium. and Cozaar Comp 100 mg/ 25 mg contains 8.48 mg (0.216 mEq) of potassium.
100 mg/ 25 mg indeholder også titandioxid (E171), quinolingult (E104) og carnaubavoks (E903).
Cozaar Comp 50 mg/ 12.5 mg and Cozaar Comp 100 mg/ 25 mg also contain, Titanium dioxide (E171), Quinoline yellow aluminum lake (E104), and Carnauba wax (E903)
Hydroxypropylcellulose, hypromellose og titandioxid) samt Carnaubavoks carnaubavoks.
Cozaar Comp 100 mg/ 12.5 mg also contain: white color concentrate (or the individual ingredients of the concentrate: hydroxypropyl cellulose, hypromellose and titanium dioxide) and carnauba wax.
(E903), titandioxid (E171).
Carnauba wax (E903), Titanium dioxide (E171)
Titandioxid (E171), quinolingult (E104) og carnaubavoks (E903).
Cozaar Comp 100 mg/ 25 mg also contain:, Titanium dioxide (E171), Quinoline yellow aluminum lake (E104), and Carnauba wax (E903)
100 mg/ 12, 5 mg, Cozaar Comp.
Cozaar Comp 50 mg/ 12.5 mg, Cozaar Comp 100 mg/ 25 mg:
100 mg/ 25 mg:
Cozaar Comp 100 mg/ 12.5 mg:
33 3 år.
2 years
Opbevares i den originale yderpakning.
34 Store in the original package.
50 mg/ 12, 5 mg - PVC/ PE/ PVDC blisterpakninger med aluminiumsfolie i pakninger à 4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 98 eller 280 tabletter.
Cozaar Comp 50 mg/ 12.5 mg - PVC/ PE/ PVDC blister packages with aluminum foil lidding in packs of 4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 98, or 280 tablets.
HDPE- beholder à 100 tabletter.
HDPE bottles of 100 tablets.
100 mg/ 12, 5 mg - PVC/ PE/ PVDC blisterpakninger med aluminiumsfolie i pakninger à 14, 15, 28, 30, 50, 56, 84, 90, 98, 280 tabletter.
Cozaar Comp 100 mg/ 12.5 mg - PVC/ PE/ PVDC blister packages with aluminum foil lidding in packs of 14, 15, 28, 30, 50, 56, 84, 90, 98, 280 tablets.
Cozaar 100 mg/ 25 mg - PVC/ PE/ PVDC blisterpakninger med aluminiumsfolie i pakninger à 7, 14, 28, 30, 50, 56, 84, 90, 98 eller 280 tabletter.
Cozaar Comp 100 mg/ 25 mg > - PVC/ PE/ PVDC blister packages with aluminum foil lidding in packs of 7, 14, 28, 30, 50, 56, 84, 90, 98, or 280 tablets.
6. 6 Regler for destruktion og anden håndtering
6.6 Special precautions for disposal< and other handling >
< {DD/ MM/ ÅÅÅÅ} > < {DD måned ÅÅÅÅ} >
< {DD/MM/YYYY} > < {DD month YYYY} >
35 MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
35 LABELLING
Ydre karton for Cozaar Comp.
36 PARTICULARS TO APPEAR ON THE OUTER PACKAGING